Diffuse reduction of spleen density is a novel prognostic marker for intrahepatic cholangiocarcinoma after curative resection

doi:10.4251/wjgo.v13.i8.929

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4620)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-1) series.

Item

Count

PDF

242

WORD

167

HTML

2023

Figures (1-6)

263

Tables (1-1)

269

Sum=2964

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

536

Download

1120

Sum=1656

Aug 15, 2021 (publication date) through Nov 11, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Aug 15, 2021; 13(8): 929-942
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.929

Full Size Figure Download Figure

Figure 3 Kaplan–Meier curves of overall survival and recurrence-free survival comparisons between patients with and without diffuse reduction of spleen density in the cohort. A: Overall survival; B: Recurrence-free survival. DROSD: Diffuse reduction of spleen density.

Citation: Deng LM, Wang Y, Yang JH, Li JL, Chen ZY, Bao WM, Chen KY, Yao XF, Zheng CM, Zheng JY, Yu ZP, Jin B, Chen G. Diffuse reduction of spleen density is a novel prognostic marker for intrahepatic cholangiocarcinoma after curative resection. World J Gastrointest Oncol 2021; 13(8): 929-942
URL: https://www.wjgnet.com/1948-5204/full/v13/i8/929.htm
DOI: https://dx.doi.org/10.4251/wjgo.v13.i8.929